Use virtual visits to enhance the patient centricity of clinical trials – MedCity News
Posted: October 13, 2020 at 9:58 am
After a concerted effort by our industry over the last several years, sponsors, clinical research organizations (CROs) and clinical trial suppliers have added patient centricity to our vocabulary and study planning.
The shift to not just think about the patient but think as the patient is a critical effort to advance clinical research for and with patients. Patient-focused strategies such as protocol design insights, focus groups, satisfaction surveys, indication-specific content and study results sharing continue to evolve as potential standard approaches in research studies. These strategies enable more patient-centric approaches and are important but are not the only solutions required to be patient centric.
Participants travel to specific research locations (sometimes an hour or more away) at specific times (which often means taking time off of work) to conduct assessments that in many cases can be conducted remotely. In between study visits, it can be challenging for patients to provide clinically relevant information and quickly connect with their sites to complete study activities. 15% to 40% of patients enrolled in clinical studies drop out before they are completed, delaying study timelines and new product launches. These delays can cost $600,000 per day in lost revenue opportunities for a niche drug and as much as $8 million for a blockbuster drug, underscoring the importance of patient retention in clinical trials.
Fortunately, there is an additional way to improve engagement, retention and timelines that has been brought to the forefront as a result of the Covid-19 pandemic. Telehealth virtual visits have been accelerating as an option available for sponsors throughout the global clinical research industry. Rather than requiring participants to go to sites for every check-in or visit, many clinical trial leaders have turned to telehealth, not only to keep operations steady during challenging times but also to adopt and offer an additional patient-centric approach to studies.
Bringing the study visits to patientsThe pandemic gave a new sense of urgency to patient-centric solutions that extended the site into a patients home safely. In the midst of the rampant spread of Covid-19 and fears about contracting it, many patients were reluctant to travel to a centralized location and some patients had concerns with home visits. As unemployment numbers increased due to the shutdown, participants (and their loved ones) were also more reluctant to take time off work and travel outside of their community. Yet it was critical that these life-changing, and in some cases life-saving, clinical trials continue.
Advances in telehealth offered an ideal solution. Rather than bringing patients to the clinic, sponsors and CROs could bring the study visits to patients. This approach enabled visits to continue (albeit remotely) to capture as many of the protocol-required assessments as possible without in-person interaction. Throughout the pandemic, our study stakeholders have been creating new habits around virtual meetings, video teleconferencing and conducting activities outside of brick-and-mortar locations.
This does not infer that in-person visits should be eliminated but does establish that patients, sites and sponsors are adopting virtual visits as an option to provide flexible approaches for study activities. This hybrid omni-channel approach that includes a mix of on-site, telehealth, phone, home health and mobile app creates a new level of convenience, flexibility and simplicity for patients, encouraging them to remain with the clinical trial.
Telehealth creates patient-centric benefitsIncorporating the use of telehealth offers many patient-centric benefits that can be used to mitigate dropout rates and help bring clinical trials to close on-time and on-budget:
Here to stayAs we continue to manage through the pandemic and plan for studies post-pandemic, it is clear that telehealth as a patient-centric approach has the ability to become a standard option for studies. By enabling a more hybrid approach to clinical trials with the added flexibility of telehealth, studies can improve patient-centricity, which will ultimately improve recruitment, engagement, and retention.
Photo: ronnachaipark, Getty Images
Original post:
Use virtual visits to enhance the patient centricity of clinical trials - MedCity News
- Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 -... - January 13th, 2021
- Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial - BioSpace - January 13th, 2021
- CF Foundation Awards Up to $2M to Eloxx Pharmaceuticals for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations... - January 13th, 2021
- FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients - BioSpace - January 13th, 2021
- Axiom Presents Clinical Studies in 2021: The changing dynamics and challenges of getting studies done rapidly Insights Session at Biotech Showcase... - January 13th, 2021
- Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of... - January 13th, 2021
- A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. - Physician's Weekly - December 26th, 2020
- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access - GlobeNewswire - December 23rd, 2020
- Rakuten Medical Enrolls First Patient in the US Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck... - December 23rd, 2020
- Innovative drug, Carrimycin, Receives FDA Approval for International, Multi-country Phase III Clinical Trial for the treatment of severe COVID-19 in... - December 23rd, 2020
- MK-7110 COVID-19 Therapeutic - PrecisionVaccinations - December 23rd, 2020
- Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients -... - December 23rd, 2020
- Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19 - CNBC - December 23rd, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 23rd, 2020
- FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 -... - December 23rd, 2020
- Orbus Therapeutics Receives US Patent for Eflornithine Formulations - GlobeNewswire - December 23rd, 2020
- Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of... - December 18th, 2020
- Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss - Business Wire - December 18th, 2020
- Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain - PRNewswire - December 15th, 2020
- Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with... - December 15th, 2020
- Novartis announces positive FDA Advisory Committee recommendation for use of Entresto to treat patients with HFpEF - GlobeNewswire - December 15th, 2020
- SCYNEXIS Announces Advancement of Ibrexafungerp's Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in... - December 10th, 2020
- Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults - DocWire News - December 10th, 2020
- Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT (sintilimab injection) for the treatment of... - December 10th, 2020
- Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST - PRNewswire - December 10th, 2020
- Biomerica's InFoods Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment - BioSpace - December 10th, 2020
- Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA - GlobeNewswire - December 10th, 2020
- Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050... - December 9th, 2020
- Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the... - December 9th, 2020
- Panbela Therapeutics, Inc. Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic... - December 9th, 2020
- 'They're trying to save people': Branford man in Pfizer COVID trial delighted to see UK roll out vaccine - CT Insider - December 9th, 2020
- Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular... - December 9th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 9th, 2020
- Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at... - December 9th, 2020
- CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual... - December 6th, 2020
- NYU Langone's Researchers Rise to the Science Challenge of the Century - NYU Langone Health - December 6th, 2020
- Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R... - December 6th, 2020
- Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma - GlobeNewswire - December 6th, 2020
- FDA Career Staff Are Delaying the Vaccine As Thousands of Americans Die - The Dispatch - December 6th, 2020
- First Patient Dosed in Appili Therapeutics' Phase 3 Clinical Trial of Avigan Tablets (Favipiravir) for the Treatment of COVID-19 in the United States... - December 3rd, 2020
- Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor - GlobeNewswire - December 3rd, 2020
- Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company's Abemaciclib at Virtual San Antonio Breast... - December 3rd, 2020
- Imago BioSciences Expands Phase 2 Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong - Business Wire - November 30th, 2020
- Kubota Vision Announces Collaborative Research Agreement with the Technological University Dublin for a Wearable Myopia-Control Device - Business Wire - November 30th, 2020
- Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review - DocWire News - November 30th, 2020
- Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Published in The... - November 30th, 2020
- Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for... - November 28th, 2020
- Which Drugs Can Be Repurposed to Combat COVID-19? - Precision Vaccinations - November 28th, 2020
- Health Canada Clears Appili Therapeutics for New Phase 3 Clinical Trial to Evaluate Avigan Tablets (Favipiravir) in the Prevention of COVID-19 in... - November 28th, 2020
- Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry... - November 28th, 2020
- Final FDA Guidance Reinforces Increased Focus On Diversity And Inclusion In Clinical Development - Food, Drugs, Healthcare, Life Sciences - United... - November 28th, 2020
- Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials - GlobeNewswire - November 28th, 2020
- How Effective Will Covid-19 Coronavirus Vaccines Be? 8 Reasons It's Too Early To Tell - Forbes - November 28th, 2020
- Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstrm... - November 23rd, 2020
- CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97... - November 23rd, 2020
- Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET - Business Wire - November 23rd, 2020
- BBB says scammers using texts about phony clinical studies in effort to steal - The Advocate - November 20th, 2020
- Meeting the Needs of Rare Disease Patients in Clinical Trials During the COVID-19 Pandemic, Upcoming Webinar Hosted by Xtalks - PR Web - November 20th, 2020
- INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo (cemiplimab) in the... - November 20th, 2020
- NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline - BioSpace - November 19th, 2020
- Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference - GlobeNewswire - November 19th, 2020
- Clinical Trials Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -... - November 19th, 2020
- Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and... - November 19th, 2020
- Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital... - November 19th, 2020
- Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with... - October 28th, 2020
- CHNC Aims to Be the Global Leader in Cannabis Clinical Trials Through a Merger with Pharmacology University - Yahoo Finance - October 28th, 2020
- Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant... - October 16th, 2020
- Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies... - October 16th, 2020
- New NIH clinical trial run by the U of M School of Public Health tests a combination of drugs to treat COVID-19 - UMN News - October 15th, 2020
- Zhittya Genesis Medicine Announces It Has Been Approved to Initiate Clinical Trials in Mexico for the Treatment of Amyotrophic Lateral Sclerosis (ALS)... - October 15th, 2020
- FDA Authorizes Phase 1 Trial of ImmunityBio's Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody... - October 15th, 2020
- Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting - GlobeNewswire - October 15th, 2020
- NIH study aims to identify promising COVID-19 treatments for larger clinical trials - National Institutes of Health - October 13th, 2020
- Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1... - October 13th, 2020
- Microbiome Therapeutics: Global Markets - GlobeNewswire - October 13th, 2020
- Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar Advanced Therapy as a First-line Treatment for Major Depressive Disorder -... - October 13th, 2020
- Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2)... - October 13th, 2020
- Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child... - October 13th, 2020
- FDA awards six grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases - FDA.gov - October 10th, 2020
- NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 Begins - National Institutes of Health - October 10th, 2020